Merrimack Completes Enrollment in Phase II Study for MM-141

Merrimack Pharmaceuticals, Inc. Price

Merrimack Pharmaceuticals, Inc. Price | Merrimack Pharmaceuticals, Inc. Quote

Zacks Rank & Key Picks

Merrimack currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in healthcare sector are VIVUS, Inc. VVUS, Bayer AG BAYRY and Regeneron Pharmaceuticals, Inc. REGN. While VIVUS sports a Zacks Rank #1 (Strong Buy), Bayer and Regeneron carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

VIVUS's loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 60 days. The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233.69%.

Regeneron's earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, over the last 60 days. The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.

Bayer's earnings per share estimates increased from $8.75 to $8.86 for 2017 and from $9.41 to $9.53 for 2018, over the last 30 days. The company delivered positive earnings surprises in three of the four trailing quarters with an average beat of 10.25%.

Looking for Stocks with Skyrocketing Upside?

 Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>